This company listing is no longer active
Goodbody Health Past Earnings Performance
Past criteria checks 0/6
Goodbody Health's earnings have been declining at an average annual rate of -0.6%, while the Pharmaceuticals industry saw earnings growing at 9.9% annually. Revenues have been growing at an average rate of 91% per year.
Key information
-0.6%
Earnings growth rate
7.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 14.1% |
| Revenue growth rate | 91.0% |
| Return on equity | -68.2% |
| Net Margin | -22.6% |
| Last Earnings Update | 30 Sep 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Goodbody Health makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 22 | 16 | -4 | 9 | 0 |
| 30 Jun 22 | 20 | -2 | 10 | 0 |
| 31 Mar 22 | 21 | -2 | 10 | 0 |
| 31 Dec 21 | 17 | -2 | 9 | 0 |
| 30 Sep 21 | 11 | -3 | 7 | 0 |
| 30 Jun 21 | 6 | -4 | 6 | 0 |
| 31 Mar 21 | 3 | -5 | 6 | 0 |
| 31 Dec 20 | 2 | -5 | 6 | 0 |
| 30 Sep 20 | 2 | -5 | 5 | 0 |
| 30 Jun 20 | 2 | -5 | 5 | 0 |
| 31 Mar 20 | 2 | -4 | 4 | 0 |
| 31 Dec 19 | 1 | -4 | 4 | 0 |
| 30 Sep 19 | 1 | -3 | 3 | 0 |
| 30 Jun 19 | 1 | -3 | 3 | 0 |
| 31 Mar 19 | 1 | -2 | 2 | 0 |
| 31 Dec 18 | 0 | -2 | 2 | 0 |
Quality Earnings: GDBY is currently unprofitable.
Growing Profit Margin: GDBY is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: GDBY is unprofitable, and losses have increased over the past 5 years at a rate of 0.6% per year.
Accelerating Growth: Unable to compare GDBY's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GDBY is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-55.3%).
Return on Equity
High ROE: GDBY has a negative Return on Equity (-68.24%), as it is currently unprofitable.